NCT00634946

Brief Summary

The purpose of this study is to determine whether SI-6603 is effective in the treatment of lumbar disc herniation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
195

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jan 2008

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 27, 2008

Completed
15 days until next milestone

First Posted

Study publicly available on registry

March 13, 2008

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

March 23, 2023

Status Verified

March 1, 2023

Enrollment Period

1.8 years

First QC Date

February 27, 2008

Last Update Submit

March 21, 2023

Conditions

Keywords

ChemonucleolysisLumbar VertebraeHernia

Outcome Measures

Primary Outcomes (1)

  • Changes in leg pain from baseline.

    13 weeks

Secondary Outcomes (1)

  • The leg pain

    At each assessment time point

Study Arms (4)

I

EXPERIMENTAL
Drug: SI-6603

II

EXPERIMENTAL
Drug: SI-6603

III

EXPERIMENTAL
Drug: SI-6603

IV

PLACEBO COMPARATOR
Drug: Placebo

Interventions

SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.

IIIIII

Placebo is administrated into the nucleus pulposus of an intervertebral disc.

IV

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with lumbar disc herniation (L4-L5 or L5-S1) as assessed by MRI and clinical symptoms corresponding to position of the impaired nerve root
  • Patients assessed as positive in the SLR test
  • Patients with sciatica in either lower leg
  • Patients with no improvement from pharmacotherapy or concomitant treatment with drug and nerve block

You may not qualify if:

  • Patients who have 2 or more lumbar disc herniations as assessed by MRI
  • Patients with "extrusion-type" or "sequestration-type" herniation in whom a rupture into the posterior longitudinal ligament is identified by MRI
  • Patients who have received nerve block within 3 weeks before screening
  • Patients who have undergone lumbar operation, chemonucleolysis, or percutaneous nucleotomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Chugoku Area

Chugoku, Japan

Location

Chubu Area

Chūbu, Japan

Location

Hokkaido Area

Hokkaido, Japan

Location

Kansai Area

Kansai, Japan

Location

Kanto Area

Kanto, Japan

Location

Kyushu Area

Kyushu, Japan

Location

Shikoku Area

Shikoku, Japan

Location

Tohoku Area

Tōhoku, Japan

Location

Related Publications (1)

  • Matsuyama Y, Chiba K, Iwata H, Seo T, Toyama Y. A multicenter, randomized, double-blind, dose-finding study of condoliase in patients with lumbar disc herniation. J Neurosurg Spine. 2018 May;28(5):499-511. doi: 10.3171/2017.7.SPINE161327. Epub 2018 Feb 9.

MeSH Terms

Conditions

Hernia

Condition Hierarchy (Ancestors)

Pathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 27, 2008

First Posted

March 13, 2008

Study Start

January 1, 2008

Primary Completion

November 1, 2009

Study Completion

August 1, 2010

Last Updated

March 23, 2023

Record last verified: 2023-03

Locations